Development of a Synthetic Hydrogel to Foster Microvascularization of an Endometriosis Microphysiological System
Advanced Healthcare Materials · 2026-06 · 15 (23)
DOI: 10.1002/adhm.202504936 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 06.05.2026. Verfasst von Lauren Pruett und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Endometriosis, Hydrogels, Microvessels. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
The ascent of novel alternative methods in drug development spotlights the dual needs for improved biological fidelity to in vivo, along with reproducibility, especially in regulatory applications. The need for pre‐clinical models of patient‐derived endometriosis lesions motivates the development of a vascularizable, completely synthetic extracellular matrix (v‐CS‐ECM) that supports morphogenesis of perfusable microvasculature in a microfluidic device, in the context of relevant lesion cells. This paper describes v‐CS‐ECM, a peptide‐modified polyethylene glycol‐based hydrogel crosslinked with a cell‐degradable peptide that achieves these dual goals. Vessels form by morphogenesis after the liquid v‐CS‐ECM precursor, containing endothelial cells and fibroblasts, is injected into the tissue compartment to encapsulate cells. Vessel formation is influenced by ECM biochemical and biophysical properties, the source of vascular cells, and microphysiological system operating conditions. The v‐CS‐ECM also supports the co‐culture of endometrial epithelial organoids and fibroblasts, and formation of microvascularized endometriosis lesion‐like structures when all cell types are co‐encapsulated in a microfluidic device with constant flow. Hence, v‐CS‐ECM has the potential to improve preclinical evaluation of endometriosis drug efficacy by enabling microvascularized patient‐derived lesion models.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
- Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
ORCID-Profile: Lauren Pruett, Laura Bahlmann, Ryan Ogi, Priyatanu Roy, Matthew Johnson, Linda Griffith
Förderung
- NIH HHS
- National Institutes of Health
Zitieren
APA
Pruett, L., Bahlmann, L., Ogi, R., Jiao, A., Roy, P., Johnson, M., Trumper, D., & Griffith, L. (2026). Development of a Synthetic Hydrogel to Foster Microvascularization of an Endometriosis Microphysiological System. Advanced Healthcare Materials, 15(23). https://doi.org/10.1002/adhm.202504936
Vancouver
Pruett L, Bahlmann L, Ogi R, Jiao A, Roy P, Johnson M, et al. Development of a Synthetic Hydrogel to Foster Microvascularization of an Endometriosis Microphysiological System. Advanced Healthcare Materials. 2026;15(23). doi:10.1002/adhm.202504936
BibTeX
@article{Pruett2026,
author = {Pruett, Lauren and Bahlmann, Laura and Ogi, Ryan and Jiao, Angela and Roy, Priyatanu and Johnson, Matthew and Trumper, David and Griffith, Linda},
title = {Development of a Synthetic Hydrogel to Foster Microvascularization of an Endometriosis Microphysiological System},
journal = {Advanced Healthcare Materials},
year = {2026},
volume = {15},
number = {23},
doi = {10.1002/adhm.202504936}
}
EUVIMED